Monika Joshi, MD, on Findings on Chemoradiation With Durvalumab in Urothelial Carcinoma

Posted: Friday, July 8, 2022

Monika Joshi, MD, of Penn State Cancer Institute, discusses the ongoing phase II INSPIRE trial, which is investigating bladder-sparing chemoradiation with durvalumab as a new treatment strategy for stage III bladder cancer in the first prospective study designed for lymph node–positive disease alone. Dr. Joshi urges her colleagues to join the study.